Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes in relation to the metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 3, Issue 2, 2005, Pages 147-173

  Drexler, Andrew J ^a,v   Nesto, Richard W ^b   Abrahamson, Martin J ^c   Bakris, George ^d   Bell, David ^e   Brunzell, John ^f   Dandona, Paresh ^g   Davidson, Jaime ^h   Fonseca, Vivian ⁱ   Fowler, Michael ^j   Frye, Robert ^k   Giles, Thomas ^l   Haffner, Steven ^m   Hollenberg, Norman ⁿ   Hsueh, Willa ^o   Law, Ronald ^p   Plutzky, Jorge ⁿ   Ratner, Robert ^q   Reusch, Jane ^r   Selwyn, Andrew ⁿ   Sowers, James ^s   Wyne, Kathleen ^t   Young, Lawrence H ^u   more..

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^c JOSLIN DIABETES CENTER   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

ⁱ TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k MAYO CLINIC   (United States)

^l LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^m UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

ⁿ BRIGHAM AND WOMEN S HOSPITAL   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

^p UNIVERSITY OF CALIFORNIA   (United States)

^q MEDSTAR RESEARCH INSTITUTE   (United States)

^r UNIVERSITY OF COLORADO   (United States)

^s University of Missouri   (United States)

^t UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^u YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v Diabetes Team Associates   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ATORVASTATIN; BIOCHEMICAL MARKER; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; NICOTINIC ACID DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; ROSIGLITAZONE; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TROGLITAZONE;

ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; BLOOD VESSEL REACTIVITY; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RESPONSE; CELL FUNCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG METABOLISM; DYSLIPIDEMIA; ENDOTHELIUM LESION; EVIDENCE BASED MEDICINE; FIBRINOLYSIS; FLUID RETENTION; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID STORAGE; LIVER TOXICITY; MEDICAL EXPERT; METABOLIC SYNDROME X; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PERIPHERAL EDEMA; PLEIOTROPY; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; WEIGHT GAIN;

EID: 24644499056     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2005.3.147     Document Type: Review

References (245)

1. Centers for Disease Control and Prevention. Prevalence of diabetes and impaired fasting glucose in adults: United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2003;52:833-837.
2. Mokdad AH, Ford ES, Bowman BA. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79.
3. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999; 281:1291-1297.
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
5. Alexander CM, Landsman PB, Teutsch SM, et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 2003;52:1210-1214.
6. Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001;104:3046-3051.
7. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
8. Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001;322:1-6.
9. Malmberg K, Rydén L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effect on mortality at 1 year. J Am Coll Cardiol. 1995;26: 57-65.
10. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412.
11. Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans Affairs Cooperative Study on Glycemic Control and Complications in type II Diabetes. Arch Intern Med 1997;157: 181-188.
12. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. 3. Clinical implications of UGDP results. JAMA 1971;218:1400-1410.
13. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001; 111:633-642.
14. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract Suppl 1995;28:103-117.
15. Olefsky JM, Saltiel AR. PPARγ and the treatment of insulin resistance. Trends Endocrinol Metab 2000;11: 362-368.
16. Zawadzki JK, Green L, Graham DJ. Thiazolidinedione-associated 15-month postmarketing hepatotoxicity. Presented at the Endocrine Society, Denver, 2001.
17. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002;25: 815-821.
18. Rubin C, Schneider R. Pioglitazone liver enzyme profile is similar to placebo in US controlled clinical trials. Diabetes 2000;49(suppl 1):A123(abst).
19. Drexler AJ, Nesto RW. Evaluating the cardiovascular effects of the thiazolidinediones and their place in the management of type 2 diabetes mellitus. Am J Med 2003;115(suppl 8A):1S-120S.
20. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001;24:683-689.
21. Eschwêge E, Richard JL, Thibult N, et al. Coronary heart disease mortality in relation with diabetes, blood glucose and plasma insulin levels. The Paris Prospective Study, ten years later. Horm Metab Res 1985;15(suppl):41-46.
22. Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002;25: 1129-1134.
23. Norhammar A, Tenerz Å, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002;359:2140-2144.
24. Bakris GL, Dole JF, Porter LE, et al. Rosiglitazone improves blood pressure in patients with type 2 diabetes mellitus. Diabetes 2000;49(suppl 1):A96(abst).
25. Füllert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study J. Clin Endocrinol Metab 2002;87:5503-5506.
26. Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-178.
27. Ovalle F, Bell DSH. Clinical evidence of thiazolidinedione-induced improvement of pancreatic β-cell function in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2002;4:56-59.
28. Carey DG, Cowin GJ, Galloway GJ, et al. Effect of rosiglitazone on insulin sensitivity, body fat distribution and liver fat in type 2 diabetic patients. Obes Res 2002;10:1008-1015.
29. Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002; 51:314-317.
30. Mayerson AB, Hundal RS, Dufour S, et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002;51: 797-802.
31. Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12.
32. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002;106:679-684.
33. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-967.
34. Turner RC, Millns H, Neil HAW, et al. Risk factors for coronary artery disease in non-insulin-dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. BMJ 1998;316:823-828.
35. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(suppl 1):S33-S50.
36. Haffner SM, Valdez RA, Hazuda HP, et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992;41:715-722.
37. Goodpaster BH, Krishnaswami S, Resnick H, et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care 2003;26:372-379.
38. Hanley AJG, Williams K, Stern MP, et al. Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. Diabetes Care 2002;25:1177-1184.
39. Reaven GM, Chen YDI, Jeppesen J, et al. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest 1993;92:141-146.
40. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
41. Fonseca V, Rosenstock J, Patwardhan R, et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000;283:1695-1702.
42. Lebovitz HE, Dole JF, Patwardhan R, et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001;86:280-288.
43. Miyazaki Y, Mahankali A, Matsuda M, et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care 2001;24:710-719.
44. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1:165-172.
45. Pavo I, Jermendy G, Varkonyi TT, et al. Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003;88:1637-1645.
46. Raskin P, Rendell M, Riddle MC, et al. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care 2001;24:1226-1232.
47. Raskin P, Rappaport EB, Cole ST, et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000;43:278-284.
48. Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis 2001;12:413-423.
49. Scherbaum WA, Goke B, for the German Pioglitazone Study Group. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study. Horm Metab Res 2002;34:589-595.
50. Schneider R, Lessem J, Lekich R. Pioglitazone is effective in the treatment of patients with type 2 diabetes. Diabetes 1999;48(suppl 1):A109(abst).
51. Wolffenbuttel BHR, Gomis R, Squatrito S, et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000;17:40-47.
52. Gould E, Cobitz A. Long-term durability of rosiglitazone as monotherapy or in combination therapy in patients with type 2 diabetes. Presented at the Endocrine Society's 84th Annual Meeting, San Francisco, 2002.
53. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with life-style intervention or metformin. N Engl J Med 2002; 346:393-403.
54. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-544.
55. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-1350.
56. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002;51:2796-2803.
57. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 2002;39:2072-2077.
58. Scheen AJ. Info-congress. Prevention of type 2 diabetes in obese patients: first results with orlistat in the XENDOS study. Rev Med Liege 2002;57:617-621.
59. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2003;26:977-980.
60. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Rev 1999;7:139-153.
61. Cnop M, Grupping A, Hoorens A, et al. Endocytosis of low-density lipoprotein by human pancreatic β cells and uptake in lipid-storing vesicles, which increase with age. Am J Pathol 2000;156: 237-244.
62. Unger RH. How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metab 1997;8: 276-282.
63. Higa M, Zhou Y-T, Ravazzola M, et al. Troglitazone prevents mitochondrial alterations, β cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1999;96:11513-11518.
64. Finegood DT, McArthur MD, Kojwang D, et al. β-cell mass dynamics in Zucker diabetic fatty rats: rosiglitazone prevents the rise in net cell death. Diabetes 2001;50:1021-1029.
65. Lister CA, Moore GBT, Piercy V, et al. Rosiglitazone, but not metformin or glibenclamide, improves glycaemic control and increases islet insulin content. Diabetologia 1999;42(suppl 1):A150(abst).
66. Porter LE, Freed MI, Jones NP, et al. Rosiglitazone improves β-cell function as measured by proinsulin/insulin ratio in patients with type 2 diabetes. Diabetes. 2000;49(suppl 1):A122(abst).
67. Porter LE, Freed MI, Jones NP, et al. Rosiglitazone reduces proinsulin/insulin ratio and improves β-cell function in type 2 diabetes. Diabetologia 2000; 43(suppl 1):A192(abst).
68. Kubo K. Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J 2002;49:323-328.
69. Viberti G, Kahn SE, Greene DA, et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25:1737-1743.
70. Jensen MD. Health consequences of fat distribution. Horm Res 1997;48(suppl 5):88-92.
71. Basu A, Basu R, Shah P, et al. Systemic and regional free fatty acid metabolism in type 2 diabetes. Am J Physiol Endrocrinol Metab 2001;280:E1000-E1006.
72. Carey DG, Jenkins AB, Campbell LV, et al. Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes 1996;45:633-638.
73. Cnop M, Landchild MJ, Vidal J, et al. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 2002;51:1005-1015.
74. Fujimoto WY, Bergstrom RW, Boyko EJ, et al. Visceral adiposity and incident coronary heart disease in Japanese-American men: the 10-year follow-up results of the Seattle Japanese-American Community Diabetes Study. Diabetes Care 1999;22:1808-1812.
75. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.
76. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-α. in human obesity and insulin resistance. J Clin Invest 1995;95:2409-2415.
77. Mohamed-Ali V, Goodrick S, Rarwesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997; 82:4196-4200.
78. Nilsson J, Jovinge S, Niemann A, et al. Relation between plasma tumor necrosis factor-α and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1998;18:1199-1202.
79. Yudkin JS, Stehouwer CDA, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19: 972-978.
80. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 1995;27:435-438.
81. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes 1994;43:1271-1278.
82. Meek SE, Nair KS, Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 1999; 48:10-14.
83. Sowers JR. Obesity and cardiovascular disease. Clin Chem 1998;44:1821-1825.
84. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus (T2DM). Diabetes. 2000;49(suppl 1):A299 (abst).
85. Bajaj M, Suraamornkul S, Pratipanawatr T, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52:1364-1370.
86. Kelley DE, McKolanis TM, Kelley CA. Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes 2002;51(suppl 2):A35(abst).
87. Miyazaki Y, Mahankali A, Matsuda M, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002;87:2784-2791.
88. 2-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002;51:1507-1514.
89. Sidell RJ, Cole MA, Draper NJ, et al. Thiazolidine-dione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002;51:1110-1117.
90. Yonemitsu S, Nishimura H, Shintani M, et al. Troglitazone induces GLUT4 translocation in L6 myotubes. Diabetes 2001;50:1093-1101.
91. Zhu P, Lu L, Xu Y, et al. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000;101:1165-1171.
92. Ayyobi AF, Knopp RH, Kahn SE, et al. Abnormal lipoprotein distribution in type 2 diabetes: comparison to insulin sensitive and resistant normals. Diabetes 2002;51(suppl 2):A150-A151(abst).
93. Ginsberg HN. Diabetic dyslipidemia: basic mechanisms underlying the common hypertriglyceridemia and low HDL cholesterol levels. Diabetes 1996; 45(suppl 3):S27-S30.
94. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
95. Ovalle F, Bell DSH. Lipoprotein effects of different thiazolidinediones in clinical practice. Endocrinol Pract 2002;8:406-410.
96. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
97. Austin MA. Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype. Curr Atheroscler Rep 2000;2:200-207.
98. Laakso M, Lehto S, Penttilä I, et al. Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes. Circulation 1993;88:1421-1430.
99. 3 subfractions with ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17:1098-1105.
100. Syvänne M, Ahola M, Lahdenperä S, et al. High-density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36:573-582.
101. Lahdenpera S, Syvanne M, Kahri J, et al. Regulation of low-density lipoprotein particle size distribution in NIDDM and coronary disease: importance of serum triglycerides. Diabetologia 1996; 39:453-461.
102. Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290:2030-2040.
103. Franz MJ, Bantle JP, Beebe CA, et al. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care 2002;25:148-198.
104. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(suppl 1):S83-S86.
105. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities of type 2 diabetes mellitus. Am J Cardiol 2002;90:947-952.
106. Herz M, Johns D, Reviriego J, et al. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medicationnaïve patients with type 2 diabetes mellitus. Clin Ther 2003;25:1074-1095.
107. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol 1998;82(suppl 12A):67U-73U; discussion 85U-86U.
108. Nass CM, Blumenthal RS. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease. Am J Manag Care 2000;6(suppl):S1247-S1256.
109. Ovalle F, Bell DSH. Differing effects of thiazolidine-diones on LDL subfractions. Diabetes 2001;50(suppl 2):A453-A454(abst).
110. Pan J, Van JT, Chan E, et al. Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. Metabolism 2002;51:1120-1127.
111. Superko HR, Krauss RM. Differential effects of nicotinic acid in subjects with different LDL subclass patterns. Atherosclerosis 1992;95:69-76.
112. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomized trial. JAMA 2000;284:1263-1270.
113. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of Diabetes Control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med 2002;162:1568-1576.
114. Guerin M, Egger P, Soudant C, et al. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux. Atherosclerosis 2002;163: 287-296.
115. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther 2002;4:145-151.
116. Simonson DC. Etiology and prevalence of hypertension in diabetic patients. Diabetes Care 1988;11: 821-827.
117. Coresh J, Wei GL, McQuillan G, et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the Third National Health and Nutrition Examination Survey (1998-1994). Arch Intern Med 2001;161:1207-1216.
118. Kohler KA, McClellan WM, Ziemer DC, et al. Risk factors for microalbuminuria in black Americans with newly diagnosed type 2 diabetes. Am J Kidney Dis 2000;36:903-913.
119. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med 2002;7:35-43.
120. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, et al. Urinary albumin excretion: an independent predictor of ischemic heart disease. Arterioscler Thromb Vasc Biol 1999;19:1992-1997.
121. Miettinen H, Haffner SM, Lehto S, et al. Proteinuria predicts stroke and other atherosclerotic vascular disease events in nondiabetic and non-insulin-dependent diabetic subjects. Stroke 1996;27:2033-2039.
122. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-1720.
123. Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;23:1478-1485.
124. Gerber P, Lubben G, Heusler S, et al. Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. Curr Med Res Opin 2003;19:532-539.
125. Ghazzi MN, Perez JE, Antonucci TK, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM. Diabetes 1997;46:433-439.
126. Ogihara T, Rakugi H, Ikegami H, et al. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives. Am J Hypertens 1995;8:316-320.
127. Reynolds LR, Konz EC, Frederich RC, et al. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. Diabetes Obes Metab 2002;4:270-275.
128. Nakamura T, Ushiyama C, Suzuki S, et al. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in type 2 diabetic patients with microalbuminuria or macroalbuminuria. Diabet Med 2001;18:308-313.
129. Nakamura T, Ushiyama C, Osada S, et al. Pioglitazone reduces urinary podoyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 2001;50:1193-1196.
130. Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-254.
131. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell 2001;104:503-516.
132. Libby P. Changing concepts of atherosclerosis. J Intern Med 2000;247:349-358.
133. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999;340:115-126.
134. Ziouzenkova O, Perrey S, Marx N, et al. Peroxisome proliferator-activated receptors in the vasculature. Curr Atheroscler Rep 2002;4:59-64.
135. Ghanim H, Garg R, Aljada A, et al. Suppression of nuclear factor-κB and stimulation of inhibitor-κB by troglitazone: evidence for an anti-inflammatory effect and a potential antiatherosclerotic effect in the obese. J Clin Endocrinol Metab 2001;86:1306-1312.
136. Aljada A, Garg R, Ghanim H, et al. Nuclear factor-κB suppressive and inhibitor-κB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antinflammatory action? J Clin Endocrinol Metab 2001;86:3250-3256.
137. Dandona P, Aljada A, Mohanty P, et al. Insulin inhibits intranuclear nuclear factor-κB and stimulates IκB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86:3257-3265.
138. Dandona P, Aljada A. A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. Am J Cardiol 2002;90:27G-33G.
139. Garg R, Kumbkarni Y, Aljada A, et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilation in obese subjects. Hypertension 2000;36:430-435.
140. Mohanty P, Aljada A, Ghanim H, et al. Rosiglitazone improves vascular reactivity, inhibits reactive oxygen species (ROS) generation, reduces p47phox subunit expression in mononuclear cells (MNC) and reduces C reactive protein (CRP) and monocyte chemotactic protein-1 (MCP-1): evidence of a potent anti-inflammatory effect. Diabetes 2001;50(suppl 2): A68(abst).
141. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complications 2002;16:401-415.
142. Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000;102:1000-1006.
143. Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002;106:653-658.
144. Hoffmeister A, Rothenbacher D, Bäzner U, et al. Role of novel markers of inflammation in patients with stable coronary heart disease. Am J Cardiol 2001;87:262-266.
145. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
146. Lindahl B, Toss H, Siegbahn A, et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. Fragmin during Instability in Coronary Artery Disease. N Engl J Med 2000;343:1139-1147.
147. Koenig W, Sunde M, Fröhlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
148. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol events in the prediction of first cardiovascular events. N Engl J Med 2002;347:1557-1565.
149. Pradhan AD, Manson JE, Buring JE, et al. C-reactive protein, interleukin-6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
150. Festa A, D'Agostino R Jr, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000;102:42-47.
151. Festa A, D'Agostino R Jr, Mykkänen L, et al. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance: the Insulin Resistance Atherosclerosis Study (IRAS). Arterioscler Thromb Vasc Biol 1999;19:562-568.
152. Freed M, Fuell D, Menci L, et al. Effect of combination therapy with rosiglitazone and glyburide on PAI-1 antigen, PAI-1 activity, and tPA in patients with type 2 diabetes. Diabetologia 2000;43(suppl 1): A267(abst).
153. Kato K, Satoh H, Endo Y, et al. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: a possible role for PPARgamma in endothelial function. Biochem Biophys Res Commun 1999;258:431-435.
154. Kernan WN, Inzucchi SE, Viscoli CM, et al. Pioglitazone improves insulin sensitivity among nondiabetic patients with a recent transient ischemic attack or ischemic stroke. Stroke 2003;34:1431-1436.
155. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-2499.
156. Brandenburg SL, Reusch JE, Felder KK, et al. Impaired fibrinolysis in premenopausal women and age-matched men with Type 2 diabetes mellitus: a pilot study. J Invest Med 2002;50:110-115.
157. Festa A, D'Agostino R Jr, Tracy RP, et al. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: The Insulin Resistance Atherosclerosis Study. Diabetes 2002;51:1131-1137.
158. Held C, Hjemdahl P, Rehnqvist N, et al. Fibrinolytic variables and cardiovascular prognosis in patients with stable angina pectoris treated with verapamil or metoprolol: results from the Angina Prognosis study in Stockholm. Circulation 1997;95:2380-2386.
159. Johansson L, Jansson JH, Boman K, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1, and tissue plasminogen activator/plasminogen activator inhibitor-1 complex as risk factors for the development of a first stroke. Stroke 2000;31:26-32.
160. Thögersen AM, Jansson JH, Boman K, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998;98:2241-2247.
161. Eitzman DT, Westrick RJ, Xu Z, et al. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery. Blood 2000;96:4212-4215.
162. Kaikita K, Fogo AB, Ma L, et al. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 2001;104:839-844.
163. Leurs PB, Stolk RP, Hamulyak K, et al. Tissue factor pathway inhibitor and other endothelium-dependent hemostatic factors in elderly individuals with normal or impaired glucose tolerance and type 2 diabetes. Diabetes Care 2002;25:1340-1345.
164. Allison BA, Nilsson L, Karpe F, et al. Effects of native, triglyceride-enriched, and oxidatively modified LDL on plasminogen activator inhibitor-1 expression in human endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:1354-1360.
165. Chen Y, Billadello JJ, Schneider DJ. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol 2000;20:2696-2701.
166. Maiello M, Boeri D, Podesta F, et al. Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 1992;41:1009-1015.
167. Reilly CF, McFall RC. Platelet-derived growth factor and transforming growth factor-beta regulate plasminogen activator inhibitor-1 synthesis in vascular smooth muscle cells. J Biol Chem 1991;266:9419-9427.
168. Samad F, Yamamoto K, Loskutoff DJ. Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo: induction by tumor necrosis factor-alpha and lipopolysaccharide. J Clin Invest 1996;97:37-46.
169. Sironi L, Mussoni L, Prati L, et al. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arterioscler Thromb Vasc Biol 1996;16:89-96.
170. Fonseca VA, Reynolds T, Hemphill D, et al. Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998;12:181-186.
171. Koshiyama H, Shimono D, Kuwamura N, et al. Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 2001;86:3452-3456.
172. Choi SH, Choi DH, Ko YK, et al. Preventive effects of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Diabetes 2003; 52(suppl 1):A19.
173. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:E5.
174. Takagi T, Yamamuro A, Tamita K, et al. Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 2002;89:318-322.
175. Takagi T, Akasaka T, Yamamuro A, et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. J Am Coll Cardiol 2000; 36:1529-1535.
176. Watson PA, Vinson C, Nesterova A, et al. Content and activity of cAMP response element-binding protein regulate platelet-derived growth factor receptor-alpha content in vascular smooth muscles. Endocrinology 2002;143:2922-2929.
177. Watson PA, Nesterova A, Burant CF, et al. Diabetes-related changes in cAMP response element-binding protein content enhance smooth muscle cell proliferation and migration. J Biol Chem 2001;276:46142-46150.
178. Hallsten K, Yki-Jarvinen H, Peltoniemi P, et al. Insulin-and exercise-stimulated skeletal muscle blood flow and glucose uptake in obese men. Obes Res 2003;11:257-265.
179. University of Pittsburgh Epidemiology Data Center. BARI 2D: a clinical study. 2002. Available: . Accessed December 18, 2002.
180. National Diabetes Information Clearinghouse. Two new federal studies related to diabetes announced. Diabetes Dateline 2002:2. Available: . Accessed January 5, 2004.
181. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovascular complications: the VA Diabetes Trial. Diabetes Care 2001;24:942-945.
182. Henry RR, Gumbiner B, Ditzler T, et al. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care 1993;16:21-31.
183. UK Prospective Diabetes Study (UKPDS) Group. UKPDS 13: relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310: 83-88.
184. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24: 758-767.
185. Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabet Med 2002;19:572-574,
186. Gould EM, Cobitz AR. Improved glycemic control and no weight gain in Mexican patients treated with rosiglitazone 4 mg/day in combination with metformin. Diabetes 2002;51(suppl 2):A98-A99(abst).
187. Richard BC, Asnani S, Desouza C, et al. Is weight gain inevitable with thiazolidinediones? Experience with very low calorie diets. Diabetes 2002;51(suppl 2):A609(abst).
188. Lebovitz HE. Differentiating members of the thiazolidinedione class: a focus on safety. Diabetes Metab Res Rev 2002;18:S23-S29.
189. Wang F, Aleksunes LM, Reagen LA, et al. Management of rosiglitazone-induced edema: two case reports and a review of the literature. Diabetes Technol Ther 2002;4:505-514.
190. Actos prescribing information. Indianapolis, IN: Eli Lilly and Company, 2003.
191. Avandia prescribing information. Philadelphia, PA: GlaxoSmithKline, 2003.
192. Guan HP, Li Y, Jensen MV, et al. A futile metabolic cycle activated in adipocytes by antidiabetic agents. Nat Med 2002;8:1122-1128.
193. Avilés-Santa L, Sinding J, Raskin P. Effects of metformin in patients with poorly controlled insulin-treated type 2 diabetes mellitus. Ann Intern Med 1999;131:182-188.
194. Yki-Järvinen H, Ryysy L, Nikkilä K, et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized, controlled trial. Ann Intern Med 1999;130:389-396.
195. Martens FMAC, Visseren FLJ, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002;62:1463-1480.
196. Adams M, Montague CT, Prins JB, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997;100:3149-3153.
197. Sewter CP, Blows F, Vidal-Puig A, et al. Regional differences in the response of human pre-adipocytes to PPARgamma and RXRalpha agonists. Diabetes 2002;51:718-723.
198. Asnani S, Richard BC, Desouza C, et al. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Curr Med Res Opin 2003;19:609-613.
199. Hensrud DD. Dietary treatment and long-term weight loss and maintenance in type 2 diabetes. Obes Res 2001;9(suppl 4):348S-353S.
200. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998;21:1288-1294.
201. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002; 25:1033-1041.
202. McNulty SJ, Ur E, Williams G. A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 2003;26:125-131.
203. Serrano-Rios M, Melchionda N, Moreno-Carretero E. Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sulphonylurea therapy. Diabet Med 2002;19:119-124.
204. Dogterom P, Jonkman JG, Vallance SE. Rosiglitazone: no effect on erythropoiesis or premature red cell destruction. Diabetes 1999;48(suppl 1):A98(abst).
205. Belcher G, Matthews DR. Safety and tolerability of pioglitazone. Exp Clin Endocrinol Diabetes 2000; 108(suppl 2):S267-S273.
206. Werner AL, Travaglini MT. A review of rosiglitazone in type 2 diabetes mellitus. Pharmacotherapy 2001;21:1082-1099.
207. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003;108:2941-2948.
208. Buse JB. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;108:e57.
209. Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications. Endocrinol Pract 2003;9:406-416.
210. St John Sutton M, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-2064.
211. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002;22:924-929.
212. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001;35:123-124.
213. Wang C-H, Weisel RD, Liu PP, et al. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-1354.
214. Kennedy FP. Do thiazolidinediones cause congestive heart failure? Mayo Clin Proc 2003;78:1076-1077.
215. Nichols GA, Hillier TA, Erbey JR, et al. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2000;24:1614-1619.
216. Tang WHW, Francis GS, Hoogwerf BJ, et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394-1398.
217. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002;2:11-19.
218. Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf 2001;24:873-888.
219. O'Brien PJ. Molecular mechanisms of quinone cytotoxicity. Chem Biol Interact 1991;80:1-41.
220. Tolman KG, Chandramouli J. Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003;7:369-379.
221. Saydah SH, Fradkin J, Cowie CC. Control of risk factors for vascular disease in U.S. adults with diabetes [abstract]. Diabetes. 2003;52(suppl 1):A228.
222. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-2012.
223. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996: results from the San Antonio Heart Study. Arch Intern Med 1999;159:1450-1456.
224. Flegal KM, Ezzati TM, Harris MI, et al. Prevalence of diabetes in Mexican Americans, Cubans, and Puerto Ricans from the Hispanic Health and Nutrition Examination Survey, 1982-1984. Diabetes Care. 1991;14(suppl 3):628-638.
225. Fujimoto WY, Leonetti DL, Kinyoun JL, et al. Prevalence of diabetes mellitus and impaired glucose tolerance among second-generation Japanese-American men. Diabetes 1987;36:721-729.
226. Gohdes D. Diabetes in North American Indians and Alaskan Natives. In: Diabetes in America, 2nd ed. Bethesda, MD: National Diabetes Data Group, NIH, 1995:683-701.
227. Zhang J, Markides KS, Lee DJ. Health status of diabetic Mexican Americans: results from the Hispanic HANES. Ethn Dis 1991;1:273-279.
228. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among U.S. adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359.
229. Haffner SM, D'Agostin R, Saad MR, et al. Increased insulin resistance and insulin secretion in nondiabetic African-Americans and Hispanics compared with non-Hispanic whites. The Insulin Resistance Atherosclerosis Study. Diabetes 1996;45:742-748.
230. Gómez-Perez FJ, Fanghanel-Salmon G, Barbosa JA, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev 2002;18:127-134.
231. Jun JK, Gong WC, Mathur R. Effects of pioglitazone on diabetes-related outcomes in Hispanic patients. Am J Health Syst Pharm 2003;60:469-473.
232. Osei K, Miller EE, Everitt DE, et al. Rosiglitazone is effective and well tolerated as monotherapy in African Americans with type 2 diabetes. Diabetes 2001;50(suppl 2):A127(abst).
233. Xixing Z, Changyu P, Guangwei L, et al. Rosiglitazone improves glycemic control in Chinese patients with type 2 diabetes mellitus in combination with sulphonylureas. Diabetes 2001; 50(suppl 2):A135(abst).
234. Jones NP, Mather R, Owen S, et al. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. Diabetologia 2000;43(suppl 1):A192(abst).
235. Miyazaki Y, Matsuda M, DeFronzo RA. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 2002;25:517-523.
236. Mizushige K, Tsuji T, Noma T. Pioglitazone: cardiovascular effects in prediabetic patients. Cardiovasc Drug Rev 2002;20:329-340.
237. Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2000; 22:1395-1409.
238. Kipnes MS, Krosnick A, Rendell MS, et al. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Am J Med 2001;111:10-17.
239. Matthews DR, Bakst AW, Weston WM, et al. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 1999;42(suppl 1):A228(abst).
240. Pan C, Gao Y, Gao X, et al. The efficacy and safety of pioglitazone hydrochloride in combination with sulphonylureas and metformin in the treatment of type 2 diabetes mellitus, a 12-week randomized multi-centres placebo-controlled parallel study. Zhonghua Nei Ke Za Zhi 2002;41:388-392.
241. Rosenstock J, Porter LE, Heise MA, et al. Type 2 diabetes in the elderly: reaching glycaemic goals with combination sulphonylurea and rosiglitazone. Presented at the International Diabetes Federation, Paris, 2003.
242. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003;115(suppl 8A):37S-41S.
243. Lyon CJ, Hsueh WA. Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 2003;115(suppl 8A):62S-68S.
244. Dandona P, Aljada A, Chaudhuri A. Vascular reactivity and thiazolidinediones. Am J Med 2003;115(suppl 8A):81S-86S.
245. Frye RL. Optimal care of patients with type 2 diabetes mellitus and coronary artery disease. Am J Med 2003;115(suppl 8A):93S-98S.